Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection
- PMID: 33280409
- PMCID: PMC7878320
- DOI: 10.1161/HYPERTENSIONAHA.120.16429
Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection
Abstract
Primary aldosteronism is an underdiagnosed cause of hypertension. Although inadequate screening is one reason for underdiagnosis, another important contributor is that clinicians may inappropriately exclude the diagnosis when screening aldosterone concentrations fall below traditionally established thresholds. We evaluated the intraindividual variability in screening aldosterone concentrations and aldosterone-to-renin ratios, and how this variability could impact case detection, among 51 patients with confirmed primary aldosteronism who had 2 or more screening measurements of renin and aldosterone on different days. There were a total of 137 screening measurements with a mean of 3 (range 2-6) per patient. The mean intraindividual variability, expressed as coefficients of variation, was 31% for aldosterone and 45% for the aldosterone-to-renin ratio. Aldosterone concentrations ranged from 4.9 to 51 ng/dL; 49% of patients had at least one aldosterone measurement below 15 ng/dL, 29% had at least 2 aldosterone measurements below 15 ng/dL, and 29% had at least one measurement below 10 ng/dL. Individual aldosterone-to-renin ratios ranged from 8.2 to 427 ng/dL per ng/mL·hour; 57% had at least one ratio below 30 ng/dL per ng/mL·hour, 27% had at least 2 ratios below 30 ng/dL per ng/mL·hour, and 24% had at least one ratio below 20 ng/dL per ng/mL·hour. Aldosterone concentrations and aldosterone-to-renin ratios are highly variable in patients with primary aldosteronism, with many screening values falling below conventionally accepted diagnostic thresholds. The diagnostic yield for primary aldosteronism may be substantially increased by recalibrating the definition of a positive screen to include more liberal thresholds for aldosterone and the aldosterone-to-renin ratio.
Keywords: aldosterone; angiotensins; diagnosis; plasma; renin.
Figures
Comment in
-
Primary Aldosteronism: Three Strikes and Out.Hypertension. 2021 Mar 3;77(3):900-903. doi: 10.1161/HYPERTENSIONAHA.120.16585. Epub 2021 Feb 10. Hypertension. 2021. PMID: 33566688 No abstract available.
Similar articles
-
Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays.J Hypertens. 2015 Dec;33(12):2500-11. doi: 10.1097/HJH.0000000000000727. J Hypertens. 2015. PMID: 26372319
-
Normokalemic hyperaldosteronism in patients with resistant hypertension.Isr Med Assoc J. 2002 Jan;4(1):17-20. Isr Med Assoc J. 2002. PMID: 11802302
-
Case detection in primary aldosteronism: high-diagnostic value of the aldosterone-to-renin ratio when performed under standardized conditions.J Hypertens. 2018 Jul;36(7):1585-1591. doi: 10.1097/HJH.0000000000001718. J Hypertens. 2018. PMID: 29528872
-
Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature.Endocrinol Metab Clin North Am. 2002 Sep;31(3):619-32, xi. doi: 10.1016/s0889-8529(02)00013-0. Endocrinol Metab Clin North Am. 2002. PMID: 12227124 Review.
-
Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension.J Hum Hypertens. 2006 Jul;20(7):482-9. doi: 10.1038/sj.jhh.1002024. Epub 2006 Apr 13. J Hum Hypertens. 2006. PMID: 16617310 Review.
Cited by
-
Adrenal Vein Sampling: Does the Location of the Non-adrenal Venous Sample Matter?Cardiovasc Intervent Radiol. 2024 Feb;47(2):194-199. doi: 10.1007/s00270-023-03647-z. Epub 2024 Jan 11. Cardiovasc Intervent Radiol. 2024. PMID: 38212421 Free PMC article.
-
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study.Circulation. 2024 Jan 9;149(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.066389. Epub 2023 Nov 30. Circulation. 2024. PMID: 38031887
-
Practical recommendations for antihypertensive therapy during the primary aldosteronism screening test.Endocrine. 2024 Jan;83(1):188-195. doi: 10.1007/s12020-023-03580-8. Epub 2023 Nov 4. Endocrine. 2024. PMID: 37924464
-
Redefining primary hyperaldosteronism as "The Syndrome of Inappropriate Aldosterone Secretion (SIALDS)": A common but unrecognized cause of hypertension.J Clin Hypertens (Greenwich). 2023 Dec;25(12):1045-1052. doi: 10.1111/jch.14740. Epub 2023 Oct 25. J Clin Hypertens (Greenwich). 2023. PMID: 37877173 Free PMC article. Review.
-
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocr Rev. 2024 Jan 4;45(1):125-170. doi: 10.1210/endrev/bnad026. Endocr Rev. 2024. PMID: 37556722 Free PMC article.
References
-
- Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G, Chrousos GP, Piaditis GP. Evidence of Primary Aldosteronism in a Predominantly Female Cohort of Normotensive Individuals: A Very High Odds Ratio for Progression into Arterial Hypertension. J Clin Endocrinol Metab. 2013;98(4):1409–1416. doi:10.1210/jc.2012-3353 - DOI - PubMed
-
- Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017;69(14):1811–1820. doi:10.1016/j.jacc.2017.01.052 - DOI - PubMed
-
- Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF. Increased Diagnosis of Primary Aldosteronism, Including Surgically Correctable Forms, in Centers from Five Continents. J Clin Endocrinol Metab. 2004;89(3):1045–1050. doi:10.1210/jc.2003-031337 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
